Further, either inhibiting TGFβ directly (TGFβ receptor blockade [SD208] or TGFβ neutralizing antibody [1D11]) or indirectly (blocking TGFβ release from bone using a bisphosphonate zoledronic acid [ZA]) prevented RyR1 oxidation and restored muscle strength in mice with breast cancer bone metastases. This evidence concerns the gene RYR1 and breast carcinoma.